1.The Preference Survey for Long-Acting Injectable Antipsychotics of Community-Dwelling Patients with Schizophrenia and their Caregivers.
Yoong LEE ; Nam Young LEE ; Tak YOUN ; Yong Seoung CHOI ; Yong Sik KIM ; In Won CHUNG
Korean Journal of Schizophrenia Research 2013;16(1):14-24
OBJECTIVE: The prescription rates of long-acting injectable (LAI) antipsychotics are very low around 1% in Korea. This study was aimed to explore the preference of LAIs in patients with schizophrenia, who are currently living in community, and their caregivers. METHODS: The patients, diagnosed with schizophrenia by DSM-IV TR and were registered in the 31 mental health centers of Gyeonggi province and their caregivers were inquired the knowledge of the LAIs. The questionnaires contained information such as demographic characteristics, history of psychiatric treatment, and so on. RESULTS: About 5,318 were registered in 31 community mental health centers of Gyeonggi province in February 2012. The questionnaires of 614 patients and 365 caregivers were gathered from 20 community mental health centers. The mean ages (+/-SD) of patients and caregivers were 41.9 (+/-10.2) and 62.2 (+/-13.4) years old, respectively. 272 patients (44.6%) had experienced the discontinuation of medications without doctor's consent. 217 patients (35.9%) and 97 caregivers (27.1%) knew about the LAIs. The preference rates for LAIs were 35.2% and 46.8% for the patients and caregivers, respectively. CONCLUSION: There is still huge discrepancy between the preference and the real prescriptions of LAIs in community-dwelling patients and their caregivers, much higher than in those of hospital settings. This study suggests that both patients and caregivers registered in the community mental health centers have a strong commitment to live in the community. The obstacles against the benefits of LAIs need to be resolved.
Antipsychotic Agents
;
Caregivers
;
Community Mental Health Centers
;
Diagnostic and Statistical Manual of Mental Disorders
;
Humans
;
Korea
;
Mental Health
;
Prescriptions
;
Surveys and Questionnaires
;
Schizophrenia
2.Serum CA 125 Levels in Patients with Impaired Renal Function.
Jong Hyeok KIM ; Yong Man KIM ; Young Tak KIM ; Joo Hyun NAM ; Jung Eun MOK
Korean Journal of Gynecologic Oncology and Colposcopy 1996;7(3):182-188
Measurement of the serum CA 125 level as a tumor marker in patients with epithelial ovarian cancer has been widely used to monitor disease status and predict survival of patient. While a number of benign gynecologic as well as benign or malignant non-gynecologic conditions are associated with elevations of serum CA 125 levels, the established normal range describes a healthy population of women. Because the metabolism and clearance of CA 125 is not well understood and mild or moderate degrees of renal impairment frequently occurs in ovarian cancer patients during treatment or course of disease, it is valuable to investigate the effect of impaired renal function on serum level of CA 125. Eighty-nine women on hemodialysis who had no other definite cause to elevate serum CA 125 level were selected at random. The age of the patients ranged from 19 to 83 and renal disease was secondary in most cases to diabetes mellitus, hypertension or glomeru-lonephritis. The creatinine clearance was less than 10cc/min for all patients. (continue)
Creatinine
;
Diabetes Mellitus
;
Female
;
Humans
;
Hypertension
;
Metabolism
;
Ovarian Neoplasms
;
Reference Values
;
Renal Dialysis
3.Non-invasive Cardiovascular Monitoring.
Korean Journal of Anesthesiology 1991;24(2):215-218
No abstract available.
4.A Short-Term In-Vitro Chemosensitivity Test for Ovarian Cancer: Nuclear Damage Assay.
Young Tak KIM ; Kwan Ja JI ; Yong Man KIM ; Joo Hyun NAM ; Jung Eun MOK
Korean Journal of Gynecologic Oncology and Colposcopy 1997;8(1):47-54
No abstract available.
Ovarian Neoplasms*
5.Symptomatic Os Subfibulare: Two Cases Reports.
Suk Ku HAN ; Nam Yong CHOI ; In Tak CHOO ; Seong Jin PARK ; Jung Ho KIM ; In Ju LEE
The Journal of the Korean Orthopaedic Association 1998;33(5):1481-1484
Os subfibulare is a accessory bone arround the lateral maleolus, but it is different from many other accessory bones in foot and ankle in its development related to trauma and frequent symptoms of ankle instability. Accessory bone is a developmental anomaly which fails to unite to main secondary ossification center and usually asymptomatic. But os subfibulare is developed by recurrent ankle sprains in younger age or non-union of avulsion fracture of anterior talofibular ligament and causes instability of ankle. We experienced two cases of symptomatic os subfibulare in adolecents and report them with review of literatures.
Ankle
;
Ankle Injuries
;
Foot
;
Ligaments
6.Clinicopathologic Analysis of Endometrial Carcinoma; Six year Experience.
Young Synn KIM ; Hee Bok HWANG ; Yong Man KIM ; Young Tak KIM ; Joo Hyun NAM ; Jung Eun MOK
Korean Journal of Gynecologic Oncology and Colposcopy 1996;7(3):159-172
During the 6 year period, frorn May 1, 1989 to August 31, 1995, 40 cases of endometrial carcinoma were encountered at College of Medicine, University of Ulsan, Asan Medical Center. The purpose of this study is to investigate the patient's clinical characteristics and to correlate these findings with the there histopathologic results. The results were as follows : 1. There was an increasing tendency of endometrial carcinoma during 3-year time interval between May 1, 1989 and August 31, 1995. 2. Age distribution of the patients with endometrial cancer showed; 10% for the 31s ages<40, 27.5% for the 41.
Age Distribution
;
Chungcheongnam-do
;
Endometrial Neoplasms*
;
Female
;
Humans
;
Ulsan
7.The Overxpression of p53 in gestational Trophoblastic Disease and Normal Human Placenta.
Sung Ook WHANG ; Jong Hyeok KIM ; Jooryung HUH ; Yong Man KIM ; Young Tak KIM ; Joo Hyun NAM ; Jung Eun MOK
Korean Journal of Gynecologic Oncology and Colposcopy 1997;8(3):300-314
Mutations in the tumor suppressor p53 gene are the most frequently observed genetic lesions in human cancers. It seems that wild type p53 does significant role on growth and differentiation of normal cells, Mutations and allelic loss of the p53 gene are thought to be a cause of tumor development and to be correlated with the prognostic factors in various human cancers such as breast, ovary and lung cancer. Mutant p53 proteins have a prolonged half-life and can be detected by immunohistochemistry. In case of GTD(gestational trophoblastic disease), although the mutation of p53 gene mutation was revealed to be very rare, the overexpression of p53 in immunohistochemical staining has been reported in wide range of discrepancy and its role or prognostic significance in GTD is uncertain. This study is performed to define the status of p53 overexpression in GTD and to evaluate the correlations between p53 overexpression and prognostic factors of GTD. THE RESULTS WERE AS FOLLOWS: 1. p53 overexpression was detected in none of normal placental tissue, in 58.3%(14/24) of hydatidiform mole, in 15%(6/8) of invasive mole, in 75%(3/4) of choriocarcinoma, and in 100%(1/1) of placental site trophoblastic tumor, and showed significant difference between normal placenta and GTD. We could not find any difference of the p53 overexpression between benign group(H-mole) of GTD and malignant one(invasive mole, choriocarcinoma, and placental site trophoblastic tumor) 2. In H-mole, low-risk group showed significantly higher prevalence of p53 overexpression than high-risk group did. In malignant group, there is no difference in the prevalence of p53 overexpression between early(FIGO stage I) and late(II- IV)stage-diseases, but the prevalence of p53 overexpression of low-risk group is slightly higher than that of high-risk group although we failed to find statistical significance. In conclusion, the high prevalence of p53 overexpression in GTD suggests that p53 may have a certain role in the pathogenesis of GTD or at least represent generalized DNA damage or genetic instability of GTD. And the higher prevalence of p53 overexpression in low-risk group suggests that accumulation of wild-type p53 may be related with favorable prognosis in GTD.
Breast
;
Choriocarcinoma
;
DNA Damage
;
Female
;
Genes, p53
;
Gestational Trophoblastic Disease*
;
Half-Life
;
Humans*
;
Hydatidiform Mole
;
Hydatidiform Mole, Invasive
;
Immunohistochemistry
;
Loss of Heterozygosity
;
Lung Neoplasms
;
Ovary
;
Placenta*
;
Pregnancy
;
Prevalence
;
Prognosis
;
Trophoblastic Tumor, Placental Site
;
Trophoblasts
8.A Clinical Study of Malignant Germ Cell Tumors of the Ovary.
Jun Hee NA ; Jun Sung KO ; Yong Man KIM ; Young Tak KIM ; Joo Hyeon NAM ; Jung Eun MOK
Korean Journal of Gynecologic Oncology and Colposcopy 1994;5(2):66-76
Malignant germ cell tumore occur in children and young women in reproductive age, of all the germ cell maligaanci orily pure dysgerminiomas had a high cure rate prior to 1970. This was due to the exquisite wdioseneitivity of these tumors. Multiple agent chemotherapy has dramatieally improved the pr nosis af patients with malignant ovarian germ cell tumors. The purpose of this study is to report the experience at Aaan Medical Center, department of Obstetrics and Gynecology, in 16 patients withmalignant ovarian germ cell tumors treated between July, l989 and June, l994. We analyzed the effect of age, histolagic subtype, FIGO stage, surgical pmcedurse and regimens of chemotherapy, on the prognosis of thwe tumors. The results obtained were as follows: 1. In histologic subtypes, dysgenninoma(38.0%), endodermal sinus tumor(25.0%), squamous cell carcinoma arising in mature cystic teratoma(19.0%), mixed cell tumor(6.0%), immature teratoma(6.0%), malignant ectodermal tumor in mature cystic teratoma(6.0%), were counted in order. 2. No site predilection was identifed. 3. Main initial symptoms were abdominal distension(31.0%), abdominal pain(31.0%), abdominal mass palpation(25.0%), amenorrhea(6.0%) in order. 4. Multiple tumor markers were considered to be useful in diagnosis and follow up of malignant germ cell tumors of ovary. 5. The mean age of malignant ovarian germ cell tumors was 29.5 years, and 11 cases(69.3%) of tumors under the age of 30.0 years. 6. The survival rate seemed to be decreased with advancing FIGO stage.
Carcinoma, Squamous Cell
;
Child
;
Diagnosis
;
Drug Therapy
;
Ectoderm
;
Endoderm
;
Female
;
Follow-Up Studies
;
Germ Cells*
;
Gynecology
;
Humans
;
Neoplasms, Germ Cell and Embryonal*
;
Obstetrics
;
Ovary*
;
Prognosis
;
Survival Rate
;
Biomarkers, Tumor
9.Primary transitional cell carcinoma of the fallopian tube: A case report.
Jong Hyeok KIM ; Jooryung HUH ; Yong Man KIM ; Young Tak KIM ; Joo Hyun NAM ; Jung Eun MOK
Korean Journal of Gynecologic Oncology and Colposcopy 1997;8(1):82-88
No abstract available.
Carcinoma, Transitional Cell*
;
Fallopian Tubes*
;
Female
10.DNA Ploidy Heterogeneity in Primary an Metastatic Lesion of Epithelial Ovarian Cancer.
Jong Hyeok KIM ; Joo Hyun NAM ; Joo Ryung HUH ; Yong Man KIM ; Young Tak KIM ; Jung Eun MOK
Korean Journal of Obstetrics and Gynecology 1997;40(1):170-180
Tumor DNA content measured by flow cytometry may be a predictor in the prognosis of epithelial ovarian cancer, but the results have been inconsistent. It is recognized that these conflicting results are at least partly due to the variation of DNA content between the samples from the same patient(i.e., intratumoral DNA heterogeneity). The purposes of this retrospective study were to investigate the frequency and the nature of DNA heterogeneity in epithelial ovarian cancer and to evaluate the prognostic significance of DNA heterogenetiy itself. Thirty-two patients with stage II to IV epithelial ovarian cancer who were managed at Asan Medical Center between May 1993 and April 1996 were analysed. Measurements of the nuclear DNA content were performed on samples from primary and metastatic lesion using paraffin embedded archival tissues by Epics(Coulter Inc.) flow cytometry. In two cases, the metastatic tumor was minute and did not reveal a separable peak on repeated examination. DNA heterogeneity was defined as different ploidy pattern or difference of the DNA indices than 0.15 between primary and metastatic tumors. DNA heterogeneity was found in 11 cases(36.7%), and the number of cases with homogeneous diploid and that with homogeneous aneuploid tumor were 5(16.7%) and 14(46.7%) respectively. In evaluation of prognostic significance of DNA heterogeneity using correlation with serum CA 125 level after second course of chemotherapy and residual tumor size after cytoreductive surgery among these three groups, the patients with DNA heterogeneity were considered to show intermediate prognosis between those with homogeneous diploid and homogeneous aneuploid tumor. In conclusion, DNA heterogeneity in epithelial ovarian cancer is considerable in frequency and may have prognostic value.
Aneuploidy
;
Chungcheongnam-do
;
Diploidy
;
DNA*
;
Drug Therapy
;
Flow Cytometry
;
Humans
;
Neoplasm, Residual
;
Ovarian Neoplasms*
;
Paraffin
;
Ploidies*
;
Population Characteristics*
;
Prognosis
;
Retrospective Studies